Using pneumococcal carriage data to monitor postvaccination changes in invasive disease

American Journal of Epidemiology

Volumn 178, Issue 9, 2013, Pages 1488-1495

  Weinberger, Daniel M ^a,b   Bruden, Dana T ^c   Grant, Lindsay R ^d   Lipsitch, Marc ^e   O'Brien, Katherine L ^d,f   Pelton, Stephen I ^g,h   Sanders, Elisabeth A M ⁱ   Feikin, Daniel R ^f,j  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b YALE UNIVERSITY   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

more..

Author keywords

Carriage; Conjugate vaccine, pneumococcal; Pneumococcus; Surveillance; Vaccine effectiveness; Vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGE CLASS; CHILD HEALTH; DATABASE; DEVELOPING WORLD; DISEASE INCIDENCE; DISEASE PREVALENCE; EPIDEMIOLOGY; NUMERICAL MODEL; PNEUMONIA; VACCINATION; VACCINE;

AMERICAN INDIAN; ARTICLE; CALCULATION; DISEASE CARRIER; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; NASOPHARYNGEAL CARRIAGE; NETHERLANDS; PNEUMOCOCCAL INFECTION; PREVALENCE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; UNITED STATES;

CARRIAGE; CONJUGATE VACCINE, PNEUMOCOCCAL; PNEUMOCOCCUS; SURVEILLANCE; VACCINE EFFECTIVENESS; VACCINES;

CARRIER STATE; HUMANS; INCIDENCE; MODELS, STATISTICAL; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SENTINEL SURVEILLANCE;

ALASKA; APACHE MOUNTAINS; ARIZONA; ENGLAND; MASSACHUSETTS; NAVAJO COUNTY; NETHERLANDS; TEXAS; UNITED KINGDOM; UNITED STATES; WALES;

STREPTOCOCCUS PNEUMONIAE;

EID: 84890080239     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt156     Document Type: Article

References (29)

1. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807):1962-1973.
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
3. Miller E, Andrews NJ,Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England andWales: An observational cohort study. Lancet Infect Dis. 2011;11(10):760-768.
4. Mulholland K, Satzke C. Serotype replacement after pneumococcal vaccination [letter]. Lancet. 2012; 379(9824):1387.
5. Weinberger DM, Malley R, Lipsitch M. Serotype replacement after pneumococcal vaccination - authors' reply [letter]. Lancet. 2012;379(9824):1388- 1389.
6. Simell B, Auranen K, Käyhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841-855.
7. Rinta-Kokko H, Dagan R, Givon-Lavi N, et al. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine. 2009;27(29):3831-3837.
8. Shea KM,Weycker D, Stevenson AE, et al. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine. 2011;29(45):8042-8048.
9. Weinberger D, Harboe Z, Flasche S, et al. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology. 2011;22(2):199-207.
10. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on serotypes, antibiotic resistance, and risk factors for carriage in young children. Pediatrics. 2009;124(1):e1-e11.
11. Scott JR, Millar EV, Lipsitch M, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis. 2012;205(2):280-288.
12. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a communityrandomized trial. J Infect Dis. 2007;196(8): 1211-1220.
13. Millar EV,Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008;47(8):989-996.
14. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007; 297(16):1784-1792.
15. Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J. 2008;27(4):335-340.
16. Spijkerman J, van Gils E, Veenhoven R, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011;17(4): 584-591.
17. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: A cross-sectional study. PLoS Med. 2011;8(4):e1001017.
18. Yildirim I, Stevenson A, Hsu KK, et al. Evolving picture of invasive pneumococcal disease in Massachusetts children: A comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 2012;31(10):1016-1021.
19. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50(9): 1238-1246.
20. van Deursen AM, van Mens SP, Sanders EA, et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2012;18(11): 1729-1737.
21. Wenger JD, Zulz T, Bruden D, et al. Invasive pneumococcal disease in Alaskan children: Impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J. 2010;29(3):251-256.
22. Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45(4):1225-1233.
23. Rosner B. Fundamentals of Biostatistics. Belmont, CA: Thomsen Higher Education; 2006.
24. Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010;29(2): 283-288.
25. Efron B, Morris C. Stein's paradox in statistics. Sci Am. 1977;236(5):119-127.
26. Harboe ZB, Benfield T L, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis. 2010;50(3): 329-337.
27. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100-121.
28. Hoti F, Erästö P, Leino T, et al. Outbreaks of Streptococcus pneumoniae carriage in day care cohorts in Finland - implications for elimination of transmission. BMC Infect Dis. 2009;9:102.
29. Miller E, Andrews NJ,Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127- 9131.